TARSUS PHARMACEUTICALS INC. - COMMON STOCK

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

22 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

20 фев 2024 17:00:00 Источник Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference

31 янв 2024 17:00:00 Источник Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

11 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

09 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

01 ноя 2023 18:35:08 Источник Nasdaq GlobeNewswire

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

06 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

30 авг 2023 16:30:00 Источник Nasdaq GlobeNewswire

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

24 авг 2023 09:00:00 Источник Nasdaq GlobeNewswire

Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements

10 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

01 авг 2023 22:30:33 Источник Nasdaq GlobeNewswire

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

31 июл 2023 16:29:44 Источник Nasdaq GlobeNewswire

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

12 июн 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus to Present at the Jefferies Global Healthcare Conference

05 июн 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

09 май 2023 16:05:02 Источник Nasdaq GlobeNewswire

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

08 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

03 май 2023 16:30:00 Источник Nasdaq GlobeNewswire

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

24 апр 2023 08:30:00 Источник Nasdaq GlobeNewswire

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

13 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

02 мар 2023 16:30:00 Источник Nasdaq GlobeNewswire